Replimune (REPL) Non-Current Assets (2018 - 2026)
Replimune (REPL) posted Non-Current Assets of $53.3 million for Q1 2026, little changed sequentially from $53.2 million in Q4 2025, and down 3.93% YoY from $55.4 million in Q1 2025.
Replimune (REPL) Non-Current Assets (2018 - 2026) Analysis & Trends
Replimune has reported Non-Current Assets for 9 years, with the latest figure at $53.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 3.93% year-over-year to $53.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $218.3 million (down 1.52% YoY) and the FY2026 annual result came in at $53.3 million, down 3.93% from the prior year.
- Non-Current Assets steadied at $53.3 million in Q1 2026 per REPL's latest filing, from $53.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $57.5 million in Q2 2022 and troughed at $53.2 million in Q4 2025.
- A 5-year average of $55.1 million and a median of $54.6 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets dropped 6.32% in 2023, then advanced 4.25% in 2024.
- Over 5 years, Non-Current Assets stood at $54.6 million in 2022, then retreated by 1.51% to $53.8 million in 2023, then gained by 4.25% to $56.1 million in 2024, then decreased by 5.02% to $53.2 million in 2025, then advanced by 0.06% to $53.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $53.3 million, $53.2 million, and $55.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 53.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.27 Mn |
| Dec 31, 2025 | 53.24 Mn |
| Sep 30, 2025 | 55.70 Mn |
| Jun 30, 2025 | 56.14 Mn |
| Mar 31, 2025 | 55.45 Mn |
| Dec 31, 2024 | 56.05 Mn |
| Sep 30, 2024 | 55.57 Mn |
| Jun 30, 2024 | 54.65 Mn |
| Mar 31, 2024 | 54.06 Mn |
| Dec 31, 2023 | 53.77 Mn |
| Sep 30, 2023 | 54.22 Mn |
| Jun 30, 2023 | 53.85 Mn |
| Mar 31, 2023 | 53.99 Mn |
| Dec 31, 2022 | 54.59 Mn |
| Sep 30, 2022 | 56.71 Mn |
| Jun 30, 2022 | 57.48 Mn |
| Mar 31, 2022 | 57.22 Mn |
| Dec 31, 2021 | 57.49 Mn |
| Sep 30, 2021 | 59.08 Mn |
| Jun 30, 2021 | 59.16 Mn |